Mitoglitazone
Mitoglitazone (MSDC-0160, PPAR-gamma-sparing thiazolidinedione, mitochondrial pyruvate carrier modulator)
Written by Aaron CuhaReviewed Sep 2026
Also known as: MSDC-0160, MSDC-160, M160, mTOT modulator
Extended male mouse median lifespan by 8.7 percent when started at 7 months, then failed a retest started at 18 months where it shortened female lifespan. In people it has completed a 356-patient phase 2b in type 2 diabetes and a 29-patient phase 2 in Alzheimer disease, both sponsor-run, neither followed by a phase 3.
Overview
Mitoglitazone is a thiazolidinedione designed to keep the insulin-sensitising effect of pioglitazone while largely avoiding the PPAR-gamma activation blamed for that class's fluid retention and weight gain. Its developer, Metabolic Solutions Development Company, traced the PPAR-gamma-independent action to a mitochondrial target it called mTOT, later identified as the mitochondrial pyruvate carrier (MPC1 and MPC2).
In people it reached phase 2 twice. In a 12-week phase 2b in type 2 diabetes, 356 patients were randomised to 50, 100 or 150 mg mitoglitazone, pioglitazone 45 mg or placebo, and 258 completed. The two higher doses lowered fasting glucose and HbA1c to the same extent as pioglitazone, with about half the fluid retention as judged by haematocrit and haemoglobin changes, and a smaller rise in high-molecular-weight adiponectin, which the authors read as less expansion of fat tissue. In a 12-week phase 2 in 29 non-diabetic people with mild Alzheimer disease (16 on 150 mg a day, 13 on placebo), the primary FDG-PET analysis showed no significant difference in regional brain glucose metabolism referenced to the pons or whole brain; an analysis referenced to the cerebellum showed metabolism maintained on drug and declining on placebo, which the authors called exploratory. Both trials were run by the manufacturer. No phase 3 followed either, and no Parkinson disease trial of MSDC-0160 is registered on ClinicalTrials.gov; the Parkinson work is in mice, worms and cultured neurons.
In mice, the NIA Interventions Testing Program fed mitoglitazone from 7 months of age in the 2021 cohort. Male median lifespan rose from 794 to 863 days, 8.7 percent (log-rank p = 0.015), but survival to the 90th percentile age did not change significantly (+2.9 percent, p = 0.19), and treated males were heavier than controls at 12, 18 and 24 months. Females showed a non-significant decline (median -2.3 percent, p = 0.07). In the 2022 cohort the programme retested it starting at 18 months, at a target of 300 ppm with 126 ppm achieved in the diet. Males showed no benefit (+7.8 percent median, p = 0.18). Pooled across all three sites, females on late-start mitoglitazone lived shorter lives: median -5.8 percent (p = 0.001) and 90th percentile -7.8 percent (p = 0.006). Because control females at one site lived unusually long in that cohort, the authors repeated the analysis with the other two sites only; the female harm remained significant (median -0.7 percent, p = 0.037; 90th percentile -6.45 percent, p = 0.024), as it did for pioglitazone.
Mitoglitazone is investigational and not approved anywhere.
Mechanism of action
Mitoglitazone binds the mitochondrial pyruvate carrier complex (MPC1 and MPC2), identified by photo-crosslinking proteomics as the mitochondrial target of thiazolidinediones, and has minimal affinity for PPAR-gamma. Restricting pyruvate entry into mitochondria shifts fuel use and, in the developer's model, produces insulin sensitisation without the PPAR-gamma-driven fluid retention and adipose expansion. In the human diabetes trial, the pharmacology looked like pioglitazone's on glucose with about half the haematological signature of fluid retention, which is consistent with that model. In mouse, worm and cultured human neuron models of Parkinson disease, MSDC-0160 reduced mTOR signalling, normalised autophagy, protected dopaminergic neurons and reduced glial activation. That is animal and cell data. Why it extended lifespan in male mice started at 7 months but shortened female lifespan when started at 18 months is not understood; the ITP authors note that pioglitazone, its structural parent, showed the same female harm and that the basis is not clear.
Human evidence
Two completed sponsor-run phase 2 trials, both with results posted: 356 people with type 2 diabetes for 12 weeks and 29 people with mild Alzheimer disease for 12 weeks. No phase 3, no trial longer than 12 weeks, and no trial of any kind in Parkinson disease despite frequent description of one.
- Type 2 diabetes phase 2b, 356 randomised, 258 completed 12 weeks: fasting glucose and HbA1c lowering at 100 and 150 mg equivalent to pioglitazone 45 mg; fluid retention markers about half those of pioglitazone. Manufacturer sponsored.
- An earlier phase 2a in 86 people with type 2 diabetes (90 and 220 mg against pioglitazone and placebo) is registered with results posted (NCT00760578); its primary endpoint was postprandial glucose after a mixed meal.
- Alzheimer disease phase 2, 29 randomised: primary FDG-PET endpoint not met when referenced to pons or whole brain; an exploratory cerebellum-referenced analysis favoured drug. Manufacturer sponsored. No cognitive benefit was claimed.
- Parkinson disease: no human trial of MSDC-0160 is registered on ClinicalTrials.gov. The Parkinson evidence is in mice, worms and cultured neurons.
- Programme status: no trial registered since the Alzheimer study completed in 2013. A phase 2 that is not followed by a phase 3 for a decade is a finding about the sponsor's assessment as well as about the drug.
What this does not tell you: Twelve weeks is long enough to see glucose and PET changes and far too short to see anything about ageing, cardiovascular outcomes or cancer, which are where the thiazolidinedione class has had its safety problems. The Alzheimer trial was a 29-person feasibility study and missed its primary analysis. Nothing in a person speaks to lifespan, and the mouse programme's second cohort found female harm when started late.
Reading the research record
The NIA Interventions Testing Program runs each compound in parallel at three sites (The Jackson Laboratory, the University of Michigan and UT Health San Antonio) in genetically heterogeneous UM-HET3 mice, tests both sexes, analyses them separately, pools the sites in a site-stratified log-rank test, and publishes every result whether or not the compound worked. It is publicly funded by the National Institute on Aging with no pharmaceutical sponsorship. Mitoglitazone is the ITP compound where the programme's insistence on retesting did its job. Started at 7 months in the 2021 cohort it raised male median lifespan 8.7 percent without moving 90th percentile survival, which already marked it as a compound that prevented earlier deaths rather than one that stretched the tail. Started at 18 months in the 2022 cohort, at a diet concentration that reached only 126 of the 300 ppm target, it did nothing for males and shortened female lifespan, by 5.8 percent at the median in the three-site pooling and still significantly when the site with unusually long-lived control females was removed. Pioglitazone, its parent, produced the same female harm in the same cohort. The honest reading is: one positive male result at one dose and start age, one negative retest with a sex-specific harm signal, and a dose shortfall in the retest that leaves the question of what a full late-start dose would have done open.
The human record stopped in 2013 for reasons the company has not published. Both phase 2 trials posted results, which is to its credit, and neither was followed by a phase 3. A private developer holding the patent had every commercial reason to proceed if the data supported it. The Parkinson disease story, which is repeated widely, rests entirely on a 2016 animal and cell paper; no trial in patients exists, and a page that says it is "in phase 2 for Parkinson disease" is wrong.
The evidence, charted
Fig. 1 · evidence composition
4of 8 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2013 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2026
Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice
Interventions Testing Program 2021 cohort, treatment from 7 months. Male median lifespan 863 versus 794 days (+8.7 percent, log-rank p = 0.015); 90th percentile survival +2.9 percent, not significant (p = 0.19); 149 treated males against 298 controls. Treated males were heavier at 12, 18 and 24 months. Females: median -2.3 percent, p = 0.07. NIA funded.
GeroScience - Animal2026
Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice
2022 cohort retest of mitoglitazone started at 18 months (target 300 ppm, achieved 126 ppm). Males: median +7.8 percent, p = 0.18, not significant. Females pooled across three sites: median -5.8 percent (p = 0.001), 90th percentile -7.8 percent (p = 0.006); with the site whose control females lived unusually long removed, median -0.7 percent (p = 0.037) and 90th percentile -6.45 percent (p = 0.024). Pioglitazone showed the same female harm. NIA funded.
GeroScience - Human2013
Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer
Phase 2b, 12 weeks, 258 completers of 356 randomised to 50, 100 or 150 mg mitoglitazone, pioglitazone 45 mg or placebo. Fasting glucose fell equally on the two active drugs; HbA1c reductions at 100 and 150 mg were not different from pioglitazone; haematocrit, red cell and haemoglobin changes indicating fluid retention were 50 percent smaller; HMW adiponectin rose less (p < 0.0001). Sponsored by Metabolic Solutions Development Company.
Clinical Pharmacology and Therapeutics - Human2014
An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease
29 non-diabetic people with mild Alzheimer disease randomised to 150 mg daily (n = 16) or placebo (n = 13) for 12 weeks. Primary FDG-PET analysis referenced to pons or whole brain: no significant difference. Exploratory analysis referenced to cerebellum: metabolism maintained on drug and declined on placebo in cingulate, parietal and temporal regions. Sponsor-run.
Current Alzheimer Research - Human2013
Phase 2B dose-ranging study of mitoglitazone in type 2 diabetes
Registry record: 356 enrolled, completed December 2011, results posted March 2013, sponsor Metabolic Solutions Development Company. Primary endpoint change in fasting plasma glucose at week 12.
ClinicalTrials.gov - Human2014
3-month study of MSDC-0160 on brain glucose utilization, cognition and safety in Alzheimer disease
Registry record: 29 enrolled, completed May 2013, results posted November 2014. No follow-on trial in Alzheimer disease is registered. No MSDC-0160 trial in Parkinson disease is registered.
ClinicalTrials.gov - In vitro2013
Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT): relationship to newly identified mitochondrial pyruvate carrier proteins
Photo-crosslinking proteomics identified MPC1 and MPC2 as the mitochondrial complex that binds thiazolidinediones; knockdown in Drosophila blocked drug action and raised haemolymph glucose. Company-authored mechanism paper.
PLoS One - Animal2016
Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease
MSDC-0160 protected dopaminergic neurons in MPTP-treated mice, a C. elegans alpha-synuclein model and cultured human midbrain neurons, reduced mTOR signalling and normalised autophagy. Animal and cell data; the source of the Parkinson interest. No human Parkinson trial has followed.
Science Translational Medicine
Frequently asked questions
Did mitoglitazone extend lifespan in the ITP?
In one cohort, in males, started at 7 months: median lifespan rose 8.7 percent (863 versus 794 days, p = 0.015) without a significant change in survival to the 90th percentile age. Retested from 18 months in the next cohort, males gained nothing and females lived shorter lives, median -5.8 percent pooled across sites, and the female harm held when the analysis excluded a site with unusually long-lived controls.
Has mitoglitazone been tested in people?
Yes. A 356-person phase 2b in type 2 diabetes found glucose lowering equal to pioglitazone with about half the fluid retention over 12 weeks, and a 29-person phase 2 in mild Alzheimer disease missed its primary FDG-PET analysis over 12 weeks. Both were run by the manufacturer between 2008 and 2013. No phase 3 followed.
Is it in trials for Parkinson disease?
No. The Parkinson data are from mice, C. elegans and cultured neurons in a 2016 paper. ClinicalTrials.gov lists no MSDC-0160 trial in Parkinson disease.
How is it different from pioglitazone?
It is a structural analogue that keeps the action on the mitochondrial pyruvate carrier and largely drops PPAR-gamma binding, which in the diabetes trial translated to similar glucose lowering with roughly half the fluid-retention signature. In the ITP's 2022 cohort both drugs shortened female lifespan when started late, so the shared mitochondrial action, not PPAR-gamma, is the more likely explanation for that harm, though the authors say the basis is not clear.